Mag. Dr. Alexander Pretsch, BSc. (Chief Executive Officer)
Alexander is a leading expert in medicinal chemistry and the development of antibiotics with more than 15 years of experience in drug discovery and microbial research in academia and industry. He is a successful biotech entrepreneur and CEO, and has founded two drug development companies prior to Oxford Antibiotics Group (SeaLife Pharma and Marinomed). He studied biomedicine, biotechnology and biology with focus on infectious diseases and drug development. Alex is member of several international Advisory Boards, was an Executive Board member in Pharmasea, an international discovery program, and has been teaching drug development at national and international universities for more than ten years.
Mag. Dr. Miroslav Genov (Chief Scientific Officer)
Miroslav has an excellent track record of leading the chemical synthesis and medicinal chemistry programs for various drug development programs and has more than 20 years of experience working in industrial and academic settings. Before joining the Oxford Antibiotics Group, Miro held the position of Head of Medicinal Chemistry at SeaLife Pharma, Miro holds a PhD in Chemistry from the Institute of Organic Chemistry with Centre of Phytochemistry at the Bulgarian Academy of Sciences. Before joining the Department of Inorganic Chemistry at the University of Valladolid, Spain as Assistant Professor, Miro trained as Research Fellow with Professor Andreas Pfaltz at the University of Basel, Switzerland and at the Max Plank Institute for Coal Research, Mülheim an der Ruhr, Germany.
MSc. Dagmar Pretsch, BSc. (Head of Laboratory)
Dagmar is a leading expert in C. elegans drug screening platforms and is responsible for the optimization and expansion of the Oxford Antibiotic Group’s screening platforms. Dagmar has over ten years of experience in drug screens using antibacterial, antiviral and cellular assays. In her previous roles in biotech and pharma, Dagmar was involved in a number of drug development programs in antibiotics, and neurological disorders. Dagmar holds an MSc in neurobiology and a BSc. in biomedicine and biotechnology from the University of Vienna and worked at the Department of Pharmacognosy at the University of Vienna before joining Oxford Antibiotics Group. For her PhD thesis, Dagmar was awarded a prestigious Doc-fellowship from the Austrian Academy of Sciences.
Mag. Dr. Jutta Roth (Head of Business Development)
Jutta holds a PhD in Biology (Molecular Genetics) and has received her training at the National Institute of Medical Research, Yale University, and Salzburg University. Jutta has more than ten years of experience working on the intersection of academia and industry and has managed large scale strategic alliances between the University of Oxford and the Pharmaceutical Industry. Before joining, Oxford Antibiotics Group, Jutta was the Head of Strategic Development at Barts and The London School of Medicine and Dentistry (Queen Mary University of London) and also Director of Partnerships at the Centre for Population Genomic Medicine, a collaboration between Queen Mary University of London, King’s College London, and University College London. In both roles, Jutta set up programs that increased QMUL’s interactions with industry in research and teaching, and implemented new funding models for collaborative research.